# Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

> **NCT06678230** · PHASE2 · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06678230
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-11
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06678230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06678230, "Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06678230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*